OB/GYN Clinical Alert – July 1, 2020
July 1, 2020
View Issues
-
Is RhoGAM Needed for Rh-Negative Women Experiencing First-Trimester Pregnancy Loss or Induced Abortion?
In this prospective cohort pilot study, the authors validated a flow cytometry protocol for detecting fetal red blood cells and determined that fetal red blood cell exposure in first-trimester uterine aspiration was well below the calculated threshold for maternal Rh sensitization.
-
Does a Standardized Recovery Bundle After Cesarean Delivery Decrease Length of Stay?
Implementation of an enhanced recovery bundle after cesarean delivery reflected diverse positive outcomes. However, length of stay was reduced only by an average of two hours.
-
Fezolinetant Shows Positive Response in Vasomotor Symptoms Associated with Menopause
A phase 2b trial using seven dosing regimens of a novel neurokinin-3 receptor antagonist, fezolinetant, shows statistically significant improvement in vasomotor symptoms vs. placebo in postmenopausal women.
-
A New Treatment for Recurrent Bacterial Vaginosis?
In this randomized, controlled trial of 228 women, Lactobacillus crispatus CTV-05 (Lactin-V) applied vaginally for 11 weeks reduced the incidence of recurrent bacterial vaginosis from 45% in the placebo arm to 30% in the Lactin-V arm.
-
A Note from OB/GYN Clinical Alert’s New Editor
Rebecca Allen, MD, MPH, begins role as editor.
-
We’d Love to Hear From You!
Please complete our annual reader survey (https://bit.ly/2XYHWdM).